The cyclooxygenase (COX) pathway converts a fatty acid found in cell membranes into a family of signaling molecules called prostaglandins, and those prostaglandins touch nearly every organ system in the body. They help protect the stomach lining, regulate blood flow through the kidneys, control platelet clumping in the bloodstream, drive fever in the brain, and amplify inflammation at injury sites. Blocking this pathway is exactly how aspirin, ibuprofen, naproxen, and the newer “coxib” drugs reduce pain and swelling, but the same blockade also explains why those medications carry risks for the gut, the heart, and the kidneys. Understanding what the pathway does in healthy tissue makes the trade-offs of shutting it down considerably clearer.
Two Enzymes, Two Reputations
The pathway runs through two closely related enzymes, COX-1 and COX-2. For years the textbook shorthand was simple: COX-1 is always on, doing housekeeping chores, while COX-2 switches on only when there is inflammation. That picture is an oversimplification. COX-1 does show up in blood vessels, platelets, smooth muscle cells, and the cells lining body cavities, but COX-2 is constitutively present in several organs, including the kidney, the brain, and parts of the reproductive tract.1PubMed Central. Cyclooxygenase in normal human tissues–is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? The old framing that COX-1 makes “good” prostaglandins while COX-2 makes “bad” ones has caused real confusion, because drugs designed to spare COX-1 and knock out COX-2 turned out to disrupt important everyday functions that COX-2 was quietly handling all along.2PubMed Central. Cyclooxygenases: structural and functional insights
Both enzymes do the same basic chemistry: they grab arachidonic acid (a fatty acid freed from the cell membrane when a cell is stressed or stimulated) and convert it first into an unstable intermediate, then into a range of prostaglandins and a compound called thromboxane. Which prostaglandin a given cell ultimately produces depends on the cell type and which downstream enzymes it has available, not on whether it was COX-1 or COX-2 that did the initial conversion.
What the Pathway Does in Blood Vessels and Platelets
One of the pathway’s most consequential jobs is balancing blood clotting against blood flow. Platelets, the small cell fragments that initiate clots, use COX-1 to make thromboxane A2, a molecule that causes blood vessels to constrict and platelets to stick together. Meanwhile, the cells lining blood vessel walls use COX-2 to produce prostacyclin, which does the opposite: it relaxes vessels and discourages platelet clumping.3PubMed. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation This tug-of-war between thromboxane and prostacyclin keeps blood flowing smoothly under normal conditions. Tip the balance too far toward thromboxane (by knocking out prostacyclin), and clot risk rises. Tip it too far the other way (by blocking thromboxane), and bleeding becomes more likely. Every COX-targeting drug shifts this balance in one direction or the other, which is why cardiovascular side effects have been such a persistent concern.
Protecting the Stomach
Your stomach secretes hydrochloric acid strong enough to dissolve food, yet the stomach lining itself doesn’t get digested. Prostaglandins are a major reason why. They stimulate the mucus and bicarbonate layer that coats the stomach wall, keep blood flowing to the gastric lining so damaged cells get replaced quickly, and help regulate acid secretion. Both COX-1 and COX-2 contribute to this defense system.4PubMed. Role of cyclooxygenase isoforms in gastric mucosal defence When you take a drug that suppresses prostaglandin production in the stomach, the mucus barrier thins, blood flow decreases, and the lining becomes more vulnerable to acid-related damage. That vulnerability shows up clinically as everything from mild heartburn to bleeding ulcers.5PubMed. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself?
Kidney Blood Flow and Blood Pressure
The kidneys are quietly one of the organs most dependent on COX-2 activity. COX-2-derived prostaglandins help keep renal arteries open, regulate how much sodium you excrete, and influence the release of renin, a hormone that controls blood pressure.6PubMed. Cyclooxygenases, the kidney, and hypertension In animal studies, blocking COX-2 activity caused a clear and rapid drop in blood flow to both the inner and outer regions of the kidney.7PubMed Central. Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway When sodium intake is low or when someone is mildly dehydrated, the kidneys lean on COX-2 even more heavily to maintain filtration. In one study, COX-2 inhibition during low-sodium conditions reduced both kidney filtration and blood flow by roughly a third.8PubMed. Role of cyclooxygenase-2 in the prolonged regulation of renal function This is why people who are dehydrated, on diuretics, or have existing kidney problems are at the highest risk of kidney trouble from anti-inflammatory drugs.
Fever and the Brain
When you have an infection, immune cells release signaling molecules that travel to the brain. In response, endothelial cells lining blood vessels in the hypothalamus ramp up COX-2 activity and start producing prostaglandin E2. That prostaglandin acts on specific receptors in the brain’s thermostat, the median preoptic nucleus, and raises the body’s temperature set point, producing fever.9PubMed. Inflammation-induced fever depends on prostaglandin E2 production by brain endothelial cells and EP3 receptors in the median preoptic nucleus of the hypothalamus This is why aspirin, ibuprofen, and acetaminophen all reduce fever: they all interfere with prostaglandin production in the brain, even though they differ in almost every other respect.
How Aspirin Works Differently From Other NSAIDs
All traditional NSAIDs (ibuprofen, naproxen, diclofenac, and others) block COX enzymes by physically sitting in the active site and preventing arachidonic acid from getting in. Their binding is reversible: once the drug is cleared from the bloodstream, the enzyme recovers and starts working again. Aspirin does something fundamentally different. It permanently attaches an acetyl group to a specific amino acid inside the enzyme’s active site, permanently disabling it.10PubMed Central. Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation The body has to make entirely new COX enzyme molecules to restore function.11PubMed. Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems
This matters enormously for platelets. Platelets are cell fragments with no nucleus, so they cannot produce new proteins. Once aspirin disables the COX-1 in a platelet, that platelet can no longer make thromboxane for the rest of its roughly ten-day lifespan. A single low-dose aspirin tablet in the morning knocks out thromboxane production in a large share of circulating platelets for the rest of the day and then some. That sustained anti-clotting effect is why low-dose aspirin is used to prevent heart attacks and strokes, and also why surgeons ask patients to stop aspirin well before an operation.
There is an added twist with COX-2. When aspirin acetylates COX-2, the enzyme does not shut down entirely. Instead, it gains a modified catalytic activity and starts producing altered lipid mediators, including compounds called aspirin-triggered resolvins and lipoxins. These molecules actively promote the resolution of inflammation rather than just suppressing it.12PubMed Central. Aspirin-triggered proresolving mediators stimulate resolution in cancer Research suggests these resolution-promoting mediators may help explain some of aspirin’s long-term benefits, including evidence that they can block the migration of vascular smooth muscle cells involved in atherosclerosis.13PubMed Central. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis
The Rise and Partial Fall of COX-2 Selective Inhibitors
Because traditional NSAIDs block both COX-1 and COX-2, stomach damage was a widespread problem. The pharmaceutical industry reasoned that a drug hitting only COX-2 would relieve pain and inflammation while sparing the stomach. That logic produced a class of drugs called coxibs, including celecoxib (Celebrex) and rofecoxib (Vioxx). The drugs exploited a structural difference between the two enzymes: COX-2 has a slightly larger active site with a side pocket that COX-1 lacks, and coxibs were designed to fit snugly into that extra space.14PubMed Central. Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships15PubMed. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors
The gastric side of the gamble mostly paid off: coxibs did cause fewer ulcers than traditional NSAIDs. But the cardiovascular side was a disaster. By suppressing COX-2 in blood vessel walls, coxibs reduced prostacyclin production without touching thromboxane (which is made by COX-1 in platelets). That tipped the balance toward clotting. Studies in mice confirmed that knocking out vascular COX-2 was enough on its own to promote both high blood pressure and thrombosis, and that the damage was compounded by a secondary drop in nitric oxide, another vessel-protecting molecule.16PubMed Central. Vascular COX-2 modulates blood pressure and thrombosis in mice Clinical trials showed increased heart attacks and strokes, and rofecoxib was pulled from the market in 2004.17PubMed Central. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective Celecoxib remains available at lower doses, but the episode reshaped how regulators and clinicians think about selective COX inhibition.
Where Acetaminophen Fits In
Acetaminophen (called paracetamol outside North America) has always been the odd one out. It reduces pain and fever but barely touches inflammation, and for decades nobody could fully explain why. The picture has gotten clearer. In lab settings, acetaminophen turns out to be a weak inhibitor of both COX-1 and COX-2 when tested in broken-cell preparations, but it becomes a potent inhibitor inside intact cells when peroxide levels and arachidonic acid concentrations are low.18PubMed. Mechanisms of action of paracetamol and related analgesics Under those low-peroxide conditions, COX-2 handles most of the prostaglandin production, and acetaminophen blocks it effectively. One study in human volunteers found that an oral dose of acetaminophen inhibited COX-2 by more than 80%, a level comparable to a standard NSAID, while COX-1 inhibition topped out around 56% and never reached the threshold needed to meaningfully affect platelet function.19PubMed. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man
This profile explains several things at once. Because inflamed tissue is awash in peroxides and high concentrations of arachidonic acid, acetaminophen’s COX inhibition gets overwhelmed at the site of injury, which is why it does little for swelling. But in the brain, where peroxide levels are lower, it works well on the prostaglandin-driven fever and pain pathways. And because it never reaches the level of COX-1 blockade that would disable platelet thromboxane production, it has traditionally been considered friendlier to the stomach than a standard NSAID.20PubMed Central. Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition? That said, recent evidence suggests acetaminophen is not as blood-pressure-neutral as once believed. Like other drugs that inhibit COX-2, it can raise blood pressure in some people.21PubMed. Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, and Hypertension
Gut Damage Beyond the Stomach
For a long time, the gastrointestinal side effects of NSAIDs were framed almost entirely in terms of stomach ulcers. That framing has expanded. Researchers now recognize that NSAIDs also injure the small intestine, and the mechanism is partly different from what happens in the stomach. While stomach damage tracks closely with prostaglandin depletion, small-intestinal injury appears to involve direct effects of NSAIDs on mitochondria, the energy-producing structures inside cells.22PubMed Central. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine This is relevant because coxibs, which were designed to protect the stomach, do not necessarily protect the small intestine to the same degree. Capsule-endoscopy studies (where patients swallow a tiny camera) have found small-bowel erosions and ulcers in a meaningful fraction of chronic NSAID users, a problem that often goes undetected because it does not show up on a standard upper endoscopy.
COX-2 and Cancer
COX-2 turns up at elevated levels in a wide range of pre-cancerous and cancerous tissues, and it does not just tag along passively. The enzyme promotes angiogenesis, the growth of new blood vessels that tumors need to expand. It does so through several downstream prostaglandins, which stimulate production of vascular endothelial growth factor, help new blood vessel sprouts migrate and form tubes, protect the lining cells of new vessels from programmed death, and suppress certain anti-tumor immune responses.23PubMed. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy This is why long-term aspirin or NSAID use has been consistently linked to lower rates of colorectal cancer in epidemiological studies, and why COX-2 inhibitors have been explored as adjuncts to cancer therapy. The cardiovascular risks of coxibs have made that approach complicated, but aspirin’s unique ability to generate pro-resolving mediators from acetylated COX-2 has kept interest alive in its potential anti-cancer role.
Aspirin-Exacerbated Respiratory Disease
For a small subset of people, taking aspirin or any NSAID triggers a dramatic worsening of asthma symptoms, nasal congestion, and nasal polyps. This condition, known as aspirin-exacerbated respiratory disease (AERD), affects an estimated 7 to 15 percent of adults with asthma and involves a peculiar re-routing of the arachidonic acid pathway. Under normal circumstances, arachidonic acid gets processed through the COX pathway into prostaglandins. In people with AERD, the pathway is already skewed: there is excess activity in an alternative route called the 5-lipoxygenase pathway, which converts arachidonic acid into cysteinyl leukotrienes, potent inflammatory molecules that constrict airways.24PubMed Central. Aspirin-exacerbated respiratory disease: A review When an NSAID then shuts down whatever residual COX activity remains, even more arachidonic acid gets shunted into the leukotriene pathway, and the result can be a severe, sometimes life-threatening asthma flare. People with AERD typically need to avoid all traditional NSAIDs and are often managed with leukotriene-blocking medications instead.
COX in Reproduction
Ovulation itself resembles a mini inflammatory event. The follicle that releases an egg relies on COX-2-derived prostaglandin E2 as a key mediator. In cattle studies, broad-spectrum COX inhibitors like indomethacin reliably blocked ovulation and led to ovarian cyst formation, even at low doses. Interestingly, selective COX-2 inhibitors reduced prostaglandin E2 levels by a comparable amount yet did not block ovulation, suggesting that COX-1-derived prostaglandins or other compensatory mechanisms also contribute to the process.25PubMed Central. Effects of different cyclooxygenase inhibitors on prostaglandin E2 production, steroidogenesis and ovulation of bovine preovulatory follicles The findings are from animal models rather than human trials, but they help explain why fertility specialists sometimes advise patients to avoid NSAIDs during ovulation attempts, and why the relationship between NSAID use and human fertility remains an active area of study.
How the Discovery Unfolded
People have used willow bark, aspirin’s botanical ancestor, for pain relief for millennia, but nobody knew why it worked until 1971, when pharmacologist John Vane demonstrated that aspirin and related drugs block prostaglandin synthesis.26PubMed. The mechanism of action of aspirin That discovery, which earned Vane a Nobel Prize, came more than 70 years after Bayer first marketed aspirin as a commercial drug in 1899.27PubMed. The first 3500 years of aspirin history from its roots – A concise summary The identification of two distinct COX enzymes came later, in the early 1990s, and set off the race to build selective inhibitors. Each phase of discovery changed clinical practice: Vane’s work explained why aspirin damaged the stomach; the discovery of COX-2 made selective inhibitors possible; and the cardiovascular fallout from those selective inhibitors revealed just how much healthy tissue depends on COX-2 activity that nobody had appreciated before. The pathway keeps yielding surprises, from aspirin-triggered resolvins to the realization that acetaminophen’s mechanism maps more closely onto COX-2 inhibition than anyone expected a generation ago.